Conduit Pharma issues $5.74M convertible note to A.G.P. and amends Nirland note; conversion needs stockholder approval

CDT Equity Inc.

Issued $5,737,500 convertible note to A.G.P. for deferred commission; 5.5% interest, matures Nov 25, 2025.
Second Amendment to $2.65M Nirland note restricts conversion until stockholder approval; $100K/day penalty if meeting not held by Jan 9, 2025.
Conversion price $0.10/share (adjusted for reverse splits); up to 75M shares (Nirland) and 58M shares (A.G.P.) issuable upon conversion.
Both notes require stockholder approval under Nasdaq rules before conversion can occur.
Company can prepay notes; customary default provisions included.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.